Other
Neoplasm by Site
CI-CAN-00000003Explore in graph →
Non-malignant20,494 active trials253 approved drugs3,567 evidence items
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000003Explore in graph →
Clinical trials
92,594 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03836261 | Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL(AMPLIFY) | active not recruiting | Phase 3 | 984 | Acerta Pharma BVINDUSTRY | 27 | Dec 27, 2024 | clinicaltrials |
| NCT03150914 | Multicenter Interventional Lymphangioleiomyomatosis (LAM) Early Disease Trial(MILED) | active not recruiting | Phase 3 | 60 | University of CincinnatiOTHER |
| 1 |
| Dec 24, 2024 |
| clinicaltrials |
| NCT00798070 | Panther: A Study Comparing Biweekly and Tailored EC-T Versus Three Weekly FEC-T in Breast Cancer Patients(PANTHER) | active not recruiting | Phase 3 | 2,017 | Karolinska University HospitalOTHER | 3 | Dec 18, 2024 | clinicaltrials |
| NCT04027309 | A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy(HOVON 156 AML) | active not recruiting | Phase 3 | 777 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 13 | Dec 17, 2024 | clinicaltrials |
| NCT06465914 | A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males | active not recruiting | Phase 3 | 9,000 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Dec 12, 2024 | clinicaltrials |
| NCT03799835 | Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients(ALBAN) | active not recruiting | Phase 3 | 517 | UNICANCEROTHER | 3 | Dec 11, 2024 | clinicaltrials |
| NCT03836014 | Study Comparing Continuous Versus Fixed Duration Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma(CONFIRM) | active not recruiting | Phase 3 | 436 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Dec 6, 2024 | clinicaltrials |
| NCT01566240 | Induction Chemotherapy Plus Chemoradiation as First Line Treatment for Locally Advanced Cervical Cancer(INTERLACE) | active not recruiting | Phase 3 | 500 | University College, LondonOTHER | 5 | Dec 5, 2024 | clinicaltrials |
| NCT01444820 | Hypofractionated, Dose Escalation Radiotherapy for High Risk Adenocarcinoma of the Prostate | active not recruiting | Phase 3 | 329 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 1 | Dec 4, 2024 | clinicaltrials |
| NCT02460887 | The Role of Induction Gemcitabine and Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma in the Era of IMRT | active not recruiting | Phase 3 | 236 | Sun Yat-sen UniversityOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT04956692 | Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86) | active not recruiting | Phase 3 | 531 | Merck Sharp & Dohme LLCINDUSTRY | 16 | Dec 3, 2024 | clinicaltrials |
| NCT06709144 | Borderline of CME/D3 Dissection for Local Advanced Right-sided Colon Cancer(BLARCC) | active not recruiting | Phase 3 | 896 | Haixing Ju, MDOTHER | 1 | Nov 29, 2024 | clinicaltrials |
| NCT04923906 | Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mutations | active not recruiting | Phase 3 | 624 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 25, 2024 | clinicaltrials |
| NCT02919787 | Nordic Pancreatic Cancer Trial (NorPACT) - 1 | active not recruiting | Phase 2 / Phase 3 | 140 | Oslo University HospitalOTHER | 4 | Nov 20, 2024 | clinicaltrials |
| NCT03948789 | Phase III Study of MR-Guided Focused Ultrasound Surgery for the Treatment of Uterine Fibroids Compared to Myomectomy | active not recruiting | Phase 3 | 127 | Krankenhaus NordwestOTHER | 1 | Nov 13, 2024 | clinicaltrials |
| NCT01957436 | A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer(PEACE1) | active not recruiting | Phase 3 | 1,173 | UNICANCEROTHER | 7 | Nov 12, 2024 | clinicaltrials |
| NCT04687241 | Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations | active not recruiting | Phase 3 | 192 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 7, 2024 | clinicaltrials |
| NCT04934475 | MInimal Residual Disease Adapted Strategy(MIDAS) | active not recruiting | Phase 3 | 791 | Intergroupe Francophone du MyelomeNETWORK | 3 | Nov 7, 2024 | clinicaltrials |
| NCT04723875 | Postoperative Adjuvant Chemotherapy in Early-stage Cervical Cancer That Not Meet Criteria of Adjuvant Therapeutic According to NCCN Guideline | active not recruiting | Phase 3 | 306 | Huazhong University of Science and TechnologyOTHER | 1 | Nov 1, 2024 | clinicaltrials |
| NCT05118776 | Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM | active not recruiting | Phase 3 | 136 | Ascletis Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Oct 31, 2024 | clinicaltrials |
| NCT05566041 | A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer(REPLATINUM) | active not recruiting | Phase 3 | 292 | EpicentRx, Inc.INDUSTRY | 1 | Oct 31, 2024 | clinicaltrials |
| NCT05426486 | A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients | active not recruiting | Phase 2 / Phase 3 | 136 | Caigang LiuOTHER | 1 | Oct 30, 2024 | clinicaltrials |
| NCT06664983 | TPC Combined With Cadonilimab VS. TPC Alone in Anti-PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma | active not recruiting | Phase 3 | 84 | Sun Yat-sen UniversityOTHER | 1 | Oct 30, 2024 | clinicaltrials |
| NCT03635021 | Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer(CR-SEQUENCE) | active not recruiting | Phase 3 | 419 | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)OTHER | 1 | Oct 21, 2024 | clinicaltrials |
| NCT05177731 | Venetoclax + Decitabine vs. "7+3" Induction Chemotherapy in Young AML | active not recruiting | Phase 3 | 188 | Chen SuningOTHER | 1 | Oct 3, 2024 | clinicaltrials |
| NCT06569420 | Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLC | active not recruiting | Phase 3 | 275 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.INDUSTRY | 1 | Aug 26, 2024 | clinicaltrials |
| NCT06475820 | Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With Hemoblastosis | active not recruiting | Phase 2 / Phase 3 | 150 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Aug 23, 2024 | clinicaltrials |
| NCT03949283 | Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer | active not recruiting | Phase 3 | 150 | Cordgenics, LLCINDUSTRY | 1 | Aug 22, 2024 | clinicaltrials |
| NCT05235516 | A Study of AK104/Placebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer(AK104-305) | active not recruiting | Phase 3 | 636 | AkesoINDUSTRY | 1 | Aug 13, 2024 | clinicaltrials |
| NCT04143607 | ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC | active not recruiting | Phase 3 | 337 | Jiangsu Aosaikang Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 14, 2024 | clinicaltrials |
| NCT05077449 | A Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast Cancer | active not recruiting | Phase 3 | 300 | Xuanzhu Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 24, 2024 | clinicaltrials |
| NCT05318612 | Effectiveness of MR-guided LITT Therapy in Irresectable Glioblastoma (EMITT)(EMITT) | active not recruiting | Phase 3 | 238 | Radboud University Medical CenterOTHER | 1 | Apr 10, 2024 | clinicaltrials |
| NCT03281954 | Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo | active not recruiting | Phase 3 | 1,550 | NSABP Foundation IncNETWORK | 2 | Apr 8, 2024 | clinicaltrials |
| NCT01820858 | The Efficacy and Safety of the Postoperative Adjuvant Treatment in Patients With High-risk Stage I Endometrial Carcinoma(EC-01) | active not recruiting | Phase 3 | 300 | Ding MaOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT01996267 | Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2(TRAIN-2) | active not recruiting | Phase 3 | 437 | The Netherlands Cancer InstituteOTHER | 1 | Mar 29, 2024 | clinicaltrials |
| NCT03464305 | ASPIRIN Trial Belgium(ASPIRIN) | active not recruiting | Phase 3 | 148 | University Hospital, AntwerpOTHER | 1 | Mar 19, 2024 | clinicaltrials |
| NCT02301286 | A Trial of Aspirin on Recurrence and Survival in Colon Cancer Patients(ASPIRIN) | active not recruiting | Phase 3 | 770 | Leiden UniversityOTHER | 1 | Mar 18, 2024 | clinicaltrials |
| NCT03595592 | Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer(APTneo) | active not recruiting | Phase 3 | 650 | Fondazione MichelangeloOTHER | 4 | Mar 6, 2024 | clinicaltrials |
| NCT03507010 | Ledderhose Disease: Radiotherapy or Not?(LedRad) | active not recruiting | Phase 3 | 84 | University Medical Center GroningenOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT03413254 | Second and Third Look Laparoscopy in pT4 Colon Cancer Patients for Early Detection of Peritoneal Metastases(COLOPEC-II) | active not recruiting | Phase 3 | 389 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Feb 23, 2024 | clinicaltrials |
| NCT02565498 | Preoperative vs Postoperative IMRT for Extremity/Truncal STS | active not recruiting | Phase 3 | 210 | Mount Sinai Hospital, CanadaOTHER | 3 | Feb 20, 2024 | clinicaltrials |
| NCT02641847 | TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature | active not recruiting | Phase 2 / Phase 3 | 503 | Fudan UniversityOTHER | 1 | Jan 25, 2024 | clinicaltrials |
| NCT01584258 | Prostate Advances in Comparative Evidence(PACE) | active not recruiting | Phase 3 | 2,205 | Royal Marsden NHS Foundation TrustOTHER | 4 | Jan 19, 2024 | clinicaltrials |
| NCT05022901 | An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma | active not recruiting | Phase 3 | 30 | Delcath Systems Inc.INDUSTRY | 1 | Dec 21, 2023 | clinicaltrials |
| NCT00943423 | PET Scan in Planning Treatment in Patients Undergoing Combination Chemotherapy For Stage IA or Stage IIA Hodgkin Lymphoma(RAPID) | active not recruiting | Phase 3 | 602 | University College, LondonOTHER | 1 | Nov 30, 2023 | clinicaltrials |
| NCT03241537 | COHORT Trial in Clinical Pelivc Lymph Node Metastatic Prostate Cancer | active not recruiting | Phase 3 | 61 | Samsung Medical CenterOTHER | 1 | Nov 27, 2023 | clinicaltrials |
| NCT01678027 | Gastric Cancer Prevention in the Family Members by Helicobacter Pylori Eradication | active not recruiting | Phase 3 | 1,838 | National Cancer Center, KoreaOTHER_GOV | 1 | Nov 9, 2023 | clinicaltrials |
| NCT02407119 | Effects of H. Pylori Eradication on the Gastric Preneoplastic Lesion and Neoplasm After ESD | active not recruiting | Phase 3 | 470 | National Cancer Center, KoreaOTHER_GOV | 1 | Nov 9, 2023 | clinicaltrials |
| NCT03469674 | PORTEC-4a: Molecular Profile-based Versus Standard Adjuvant Radiotherapy in Endometrial Cancer(PORTEC-4a) | active not recruiting | Phase 3 | 550 | Leiden University Medical CenterOTHER | 8 | Oct 11, 2023 | clinicaltrials |
| NCT03324932 | Efficacy of Denosumab on Normal BMD in Women Receiving Adjuvant Aromatase Inhibitors for Early Breast Cancer | active not recruiting | Phase 3 | 160 | Kyoto Prefectural University of MedicineOTHER | 1 | Oct 6, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Dec 27, 2024source: clinicaltrials